Q-omics provides the consensus-scored CDC42P6 profile across patient tissues and cancer cell-line models. CDC42P6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CDC42P6 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, CDC42P6 RNA expression shows 17,653 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KICH, and ACC as cancer lineages where CDC42P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC42P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC42P6 survival associations across molecular data types. CDC42P6 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC42P6 RNA expression–survival associations across cancer types. High CDC42P6 expression shows unfavorable associations in BRCA, ACC, LGG and LIHC, but favorable associations in KIRC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CDC42P6 RNA expression.
This table summarizes CDC42P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CDC42P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC42P6 shows lower tumor expression in KICH, READ and THCA and higher tumor expression in LIHC, CHOL and BLCA. The KICH box plot shows higher CDC42P6 RNA expression in normal versus tumor tissue (log2 FC = −0.764, t-test p < 0.001).
This table shows molecular features associated with CDC42P6 in patient tissues and cancer cell lines. In patient samples, CDC42P6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
